Shopping Cart 0
Cart Subtotal
AED 0

Asia-Pacific Injectable Drug Delivery Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 15414

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 19818

Details

The Asia-Pacific Injectable Drug Delivery Market is accounted to reach USD 143.1 billion by 2024 from USD 56.4 billion in 2016; it is growing at a CAGR of 12.4 % in the forecast period 2017 to 2024.

The major factors driving the growth of this market are the increasing use of biologics, rising prevalence of chronic diseases, increasing occurrence of needle-stick injuries, and the benefits of injections (convenience, ease of use, and reduced pain).

The key market players for Asia-Pacific Injectable Drug Delivery Devices Market are listed below:

Pfizer and Baxter International, Inc.,

Gerresheimer AG,

Schott AG, Alkermes Plc.,

Eli Lilly and Company,

Sandoz,

Terumo Corporation,

Teva Pharmaceuticals Industries Ltd.,

Bespak, Antares Pharma,

Elcam Medical,

Haselmeier, Mylan N.V.,

Novo Nordisk,

Owen Mumford Ltd,Sanofi,

West Pharmaceutical Services, Inc,

Ypsomed Holding AG.

The market is further segmented into:

Type

Application

Usage Pattern

Mode Administration

End User

Geography

Asia-Pacific Injectable Drug Delivery Market is segmented on the basis of Type, Applications,Usage Pattern, Mode of Administration, End User and Country

Based on type, the Asia-Pacific injectable drug delivery market is segmented into devices and formulations.

By product, the needle free injectors are further segmented into fillable needle-free injectors and prefilled needle-free injectors.

By usability the needle free injector is segmented into disposable and reusable injectors.

On the basis of applications, the global Injectable drug delivery market is segmented into hormonal disorders, oncology, autoimmune diseases, orphan diseases, and others.

Based on indications into rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others.

On the basis of usage pattern the Asia-Pacific injectable drug delivery market is segmented into curative care, immunization, and others.

Based on mode of administration the market is segmented into skin, circulatory, organs and central nervous system.

On the basis of end user the Asia-Pacific injectable drug delivery market is segmented into hospitals, clinics, home care settings, research laboratories and, pharma & biotech companies.

Based on geography, the Asia-Pacific Injectable Drug Delivery Devices market is segmented into 11 geographical regions, such as,

China,

Japan,

India,

South Korea,

Australia,

Thailand,

Malaysia,

Singapore,

Indonesia,

Philippines

Covered in this report

The report covers the present scenario and the growth prospects of the Asia-Pacific Injectable Drug Delivery Devices market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

READ MORE

Table Of Content

Scope

Table Of Contents

1 Introduction

1.1. Overview Of The Asia-Pacific Injectable Drug Delivery Market

1.2. Currency And Pricing

1.3. Limitation

1.4. Markets Covered

2 Market Segmentation

2.1. Key Takeaways

2.2. Arriving At The Asia-Pacific Injectable Drug Delivery Market Size

2.2.1 Vendor Positioning Grid

2.2.2 Technology Life Line Curve

2.2.3 Market Time Line

2.2.4 Market Guide

2.2.5 Company Positioning Grid

2.2.6 Comapany Market Share Analysis

2.2.7 Multivariate Modelling

2.2.8 Standards Of Measurement

2.2.9 Top To Bottom Analysis

2.2.10 Vendor Share Analysis

2.2.11 Data Points From Key Primary Interviews

2.2.12 Data Points From Key Secondary Databases

2.3. Asia-Pacific Injectable Drug Delivery Market: Research Snapshot

2.4. Assumptions

3 Market Overview

3.1. Drivers

3.2. Restraints

3.3. Opportunities

3.4. Challenges

4 Executive Summary

5 Premium Insights

5.1. Vendor Positioning Grid And Investment Opportunities

5.2. Technololgical Advancements

5.3. Insights On Technological Developments In The North America Radiotherapymarket Market

5.4. Market Regulatory Scenario By Country

5.5. Interview Key Insights

6 Asia-Pacific Injectable Drug Delivery Market, By Type

7 Asia-Pacific Injectable Drug Delivery Market, By Therapy

8 Asia-Pacific Injectable Drug Delivery Market, By Apllication

9 Asia-Pacific Injectable Drug Delivery Market, By Technology

10 Asia-Pacific Injectable Drug Delivery Market: Geography

11 Asia-Pacific Injectable Drug Delivery Market, Company Profiles

11.1 Pfizer And Baxter International, Inc.

11.2 Gerresheimer Ag

11.3 Schott Ag, Alkermes Plc.

11.4 Eli Lilly And Company

11.5 Sandoz

11.6 Company A

11.7 Company B

11.8 Company C

11.9 Company D

11.10 Company E

11.11 Company F

11.12 Company G

11.13 Company H

11.14 Company I

11.15 Company J

11.16 Company K

11.17 Company M

11.18 Company N

11.19 Company O

12 Appendix

13 About Data Bridge Market Research

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Pfizer and Baxter International, Inc.,

Gerresheimer AG,

Schott AG, Alkermes Plc.,

Eli Lilly and Company,

Sandoz,

Terumo Corporation,

Teva Pharmaceuticals Industries Ltd.,

Bespak, Antares Pharma,

Elcam Medical,

Haselmeier, Mylan N.V.,

Novo Nordisk,

Owen Mumford Ltd,Sanofi,

West Pharmaceutical Services, Inc,

Ypsomed Holding AG.

Company Profile

Company Profile Title

The Asia-Pacific Injectable Drug Delivery Market is accounted to reach USD 143.1 billion by 2024 from USD 56.4 billion in 2016; it is growing at a CAGR of 12.4 % in the forecast period 2017 to 2024.

The major factors driving the growth of this market are the increasing use of biologics, rising prevalence of chronic diseases, increasing occurrence of needle-stick injuries, and the benefits of injections (convenience, ease of use, and reduced pain).

The key market players for Asia-Pacific Injectable Drug Delivery Devices Market are listed below:

Pfizer and Baxter International, Inc.,

Gerresheimer AG,

Schott AG, Alkermes Plc.,

Eli Lilly and Company,

Sandoz,

Terumo Corporation,

Teva Pharmaceuticals Industries Ltd.,

Bespak, Antares Pharma,

Elcam Medical,

Haselmeier, Mylan N.V.,

Novo Nordisk,

Owen Mumford Ltd,Sanofi,

West Pharmaceutical Services, Inc,

Ypsomed Holding AG.

The market is further segmented into:

Type

Application

Usage Pattern

Mode Administration

End User

Geography

Asia-Pacific Injectable Drug Delivery Market is segmented on the basis of Type, Applications,Usage Pattern, Mode of Administration, End User and Country

Based on type, the Asia-Pacific injectable drug delivery market is segmented into devices and formulations.

By product, the needle free injectors are further segmented into fillable needle-free injectors and prefilled needle-free injectors.

By usability the needle free injector is segmented into disposable and reusable injectors.

On the basis of applications, the global Injectable drug delivery market is segmented into hormonal disorders, oncology, autoimmune diseases, orphan diseases, and others.

Based on indications into rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others.

On the basis of usage pattern the Asia-Pacific injectable drug delivery market is segmented into curative care, immunization, and others.

Based on mode of administration the market is segmented into skin, circulatory, organs and central nervous system.

On the basis of end user the Asia-Pacific injectable drug delivery market is segmented into hospitals, clinics, home care settings, research laboratories and, pharma & biotech companies.

Based on geography, the Asia-Pacific Injectable Drug Delivery Devices market is segmented into 11 geographical regions, such as,

China,

Japan,

India,

South Korea,

Australia,

Thailand,

Malaysia,

Singapore,

Indonesia,

Philippines

Covered in this report

The report covers the present scenario and the growth prospects of the Asia-Pacific Injectable Drug Delivery Devices market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

READ MORE

Scope

Table Of Contents

1 Introduction

1.1. Overview Of The Asia-Pacific Injectable Drug Delivery Market

1.2. Currency And Pricing

1.3. Limitation

1.4. Markets Covered

2 Market Segmentation

2.1. Key Takeaways

2.2. Arriving At The Asia-Pacific Injectable Drug Delivery Market Size

2.2.1 Vendor Positioning Grid

2.2.2 Technology Life Line Curve

2.2.3 Market Time Line

2.2.4 Market Guide

2.2.5 Company Positioning Grid

2.2.6 Comapany Market Share Analysis

2.2.7 Multivariate Modelling

2.2.8 Standards Of Measurement

2.2.9 Top To Bottom Analysis

2.2.10 Vendor Share Analysis

2.2.11 Data Points From Key Primary Interviews

2.2.12 Data Points From Key Secondary Databases

2.3. Asia-Pacific Injectable Drug Delivery Market: Research Snapshot

2.4. Assumptions

3 Market Overview

3.1. Drivers

3.2. Restraints

3.3. Opportunities

3.4. Challenges

4 Executive Summary

5 Premium Insights

5.1. Vendor Positioning Grid And Investment Opportunities

5.2. Technololgical Advancements

5.3. Insights On Technological Developments In The North America Radiotherapymarket Market

5.4. Market Regulatory Scenario By Country

5.5. Interview Key Insights

6 Asia-Pacific Injectable Drug Delivery Market, By Type

7 Asia-Pacific Injectable Drug Delivery Market, By Therapy

8 Asia-Pacific Injectable Drug Delivery Market, By Apllication

9 Asia-Pacific Injectable Drug Delivery Market, By Technology

10 Asia-Pacific Injectable Drug Delivery Market: Geography

11 Asia-Pacific Injectable Drug Delivery Market, Company Profiles

11.1 Pfizer And Baxter International, Inc.

11.2 Gerresheimer Ag

11.3 Schott Ag, Alkermes Plc.

11.4 Eli Lilly And Company

11.5 Sandoz

11.6 Company A

11.7 Company B

11.8 Company C

11.9 Company D

11.10 Company E

11.11 Company F

11.12 Company G

11.13 Company H

11.14 Company I

11.15 Company J

11.16 Company K

11.17 Company M

11.18 Company N

11.19 Company O

12 Appendix

13 About Data Bridge Market Research

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Pfizer and Baxter International, Inc.,

Gerresheimer AG,

Schott AG, Alkermes Plc.,

Eli Lilly and Company,

Sandoz,

Terumo Corporation,

Teva Pharmaceuticals Industries Ltd.,

Bespak, Antares Pharma,

Elcam Medical,

Haselmeier, Mylan N.V.,

Novo Nordisk,

Owen Mumford Ltd,Sanofi,

West Pharmaceutical Services, Inc,

Ypsomed Holding AG.